Brief: Bristol Myers Reports Positive Phase 3 Results For Oral Mezigdomide In Relapsed Myeloma
09/03/2026 11:14
March 9 (Reuters) - Bristol-Myers Squibb Co BMY.N: BRISTOL MYERS SQUIBB ANNOUNCES POSITIVE PHASE 3 RESULTS FROM THE SUCCESSOR-2 STUDY OF ORAL MEZIGDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA BRISTOL-MYERS SQUIBB CO - MEZIKD DEMONSTRATES SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL IN RRMM BRISTOL-MYERS SQUIBB CO - SAFETY FINDINGS CONSISTENT WITH KNOWN PROFILE OF MEZIGDOMIDE AND REGIMEN Source text: ID:nBw8Ldl7La Further company coverage: BMY.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bristol-Myers Squibb Co
See all newsFactbox: Major deals involving US drugmakers and biotechs over the past decade
Brief: Bristol Myers Squibb Announces Dividend
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Izalontamab Brengitecan Shows Significant OS And PFS Improvements In TNBC And ESCC